Author

Kaitlin Anstett

Observed names: Anstett Kaitlin, Anstett, K, Anstett, Kaitlin, K. Anstett

Observed institutions: University of Toronto, Jewish General Hospital, Theratechnologies (Canada), Lady Davis Institute for Medical Research, Mark Wainberg Centre for Viral Diseases, McGill University

ORCID: 0000-0002-6051-5503

Observed ORCID: 0000-0002-6051-5503

OpenAlex ID: A5035361194

HIV drug resistance against strand transfer integrase inhibitors

2017 · Kaitlin Anstett, Bluma Brenner, et al. · Retrovirology · 189

PDF

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

2018 · the Montreal Primary HIV (PHI) Cohort Study Group, Maureen Oliveira, et al. · Retrovirology · 123

PDF

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity

2014 · T. Mesplede, N. Osman, et al. · Journal of Antimicrobial Chemotherapy · 51

PDF

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

2016 · Kaitlin Anstett, Vincent Cutillas, et al. · Journal of Antimicrobial Chemotherapy · 46

Global analysis of genetic circuitry and adaptive mechanisms enabling resistance to the azole antifungal drugs

2018 · Harley O’Connor Mount, Nicole M. Revie, et al. · PLoS Genetics · 39

PDF

Proceedings of the Frontiers of Retrovirology Conference 2016

2016 · Irena Zurnic, Sylvia Hütter, et al. · Retrovirology · 37

PDF

Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions

2015 · Kaitlin Anstett, Thibault Mesplede, et al. · Journal of Virology · 35

PDF

Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity

2015 · Kaitlin Anstett, Robert Fusco, et al. · Journal of Virology · 27

The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance

2015 · Jiaming Liang, Thibault Mesplède, et al. · Journal of Virology · 20

8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19-22 July 2015, Vancouver, Canada

2015 · Pate, KM, Pohlmeyer, C, et al. · Journal of the International AIDS Society · 17

PDF

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound

2014 · Mark Wainberg, Kaitlin Anstett, et al. · Journal of the International AIDS Society · 14

PDF

The R262K Substitution Combined with H51Y in HIV-1 Subtype B Integrase Confers Low-Level Resistance against Dolutegravir

2014 · Vincent Cutillas, Thibault Mesplede, et al. · Antimicrobial Agents and Chemotherapy · 12

PDF

HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity

2017 · Kaitlin Anstett, Bluma Brenner, et al. · Journal of Virology · 7

Efficacy and Safety of 2 Fixed Doses of Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced HIV-Positive Individuals

2024 · Edwin DeJesus, William J. Towner, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 3

Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced People Living With Multidrug-Resistant HIV-1: A Phase 3, Multicenter, Expanded Access Study

2025 · Brinda Emu, Princy N. Kumar, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 1

P-565. A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics

2025 · Princy N Kumar, Charlotte-Paige M Rolle, et al. · Open Forum Infectious Diseases · 1

P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants

2026 · Christian Caldji, Christian Marsolais, et al. · Open Forum Infectious Diseases

Correction for Anstett et al., “HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity”

2018 · Kaitlin Anstett, Bluma Brenner, et al. · Journal of Virology

鎖転移インテグラーゼ阻害剤に対するhiv薬剤耐性【jst・京大機械翻訳】

2017 · Anstett Kaitlin, Brenner Bluma, et al.

Works count: 20

Citation count: 622

H-index: 12

I10-index: 12